TABLE 1.

Univariate analysis of preoperative tumor marker levels

	CEA (ng/mL)			CA 19-9 (U/mL)			CA-125 (kU/mL)
	≤5, n (%)	> 5, n (%)	p value	≤37, n (%)	> 37, n (%)	p value	≤35, n (%)	> 3, n (%)	p value
Overall	72 (46)	85 (54)		58 (52)	53 (48)		56 (53)	50 (47)
Age, mean	53.9	57	.2	56.1	53.9	.3	55.9	55.3	.8
Gender			.2			.3			.4
Male	39 (54)	37 (44)		29 (50)	21 (40)		20 (36)	22 (44)
Female	33 (46)	48 (56)		29 (50)	32 (60)		36 (64)	28 (56)
ASA			.1			.4			.5
1	1 (2)	0 (0)		0 (0)	1 (2)		1 (2)	0 (0)
2	15 (25)	8 (12)		8 (16)	7 (16)		9 (19)	6 (14)
3	36 (61)	42 (66)		36 (74)	27 (61)		31 (66)	27 (64)
4	7 (12)	14 (22)		5 (10)	9 (21)		6 (13)	9 (22)
Recurrent disease	27 (38)	50 (60)	.01	22 (38)	33 (64)	.01	32 (57)	19 (39)	.08
Symptomatic	51 (71)	50 (59)	.1	36 (62)	35 (66)	.7	31 (55)	33 (66)	.3
CT evident disease	47 (65)	55 (66)	1	37 (65)	32 (60)	.7	27 (49)	36 (72)	.02
Prior chemotherapy	28 (39)	34 (40)	1	19 (33)	23 (43)	.3	22 (39)	17 (34)	.7
Prior HIPEC	1 (1)	8 (10)	.04	1 (2)	4 (8)	.2	3 (5)	1 (2)	.6
Prior CRS	21 (45)	29 (59)	.2	15 (40)	19 (63)	.09	16 (43)	13 (50)	.6
SPCI, median	12	14	.0002	13	16	.0001	12	15	.000007
Complete cytoreduction	57 (80)	67 (80)	1.0	48 (83)	40 (77)	.5	46 (82)	37 (76)	.5
Diagnosis			.2			.7			.7
DPAM	14 (19)	24 (29)		13 (22)	14 (27)		16 (29)	12 (24)
PMCA	58 (81)	60 (71)		45 (78)	38 (73)		40 (71)	37 (76)
High grade	37 (51)	22 (26)	.002	24 (41)	18 (34)	.4	18 (32)	21 (42)	.3
Signet cells	21 (29)	9 (11)	.004	15 (26)	9 (17)	.4	13 (23)	8 (16)	.5
Lymph node metastases	16 (30)	9 (16)	.1	10 (22)	9 (23)	1	10 (24)	6 (15)	.4